or Try an Advanced Search...

    Technical Analysis for GNLX - Genelux Corporation

    Grade Last Price % Change Price Change
    F 3.55 5.82% 0.20
    GNLX closed down 18.89 percent on Monday, April 22, 2024, on 1.91 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical GNLX trend table...
    Date Alert Name Type % Chg
    MACD Bearish Signal Line Cross Bearish 5.82%
    New 52 Week Closing Low Bearish 5.82%
    180 Bearish Setup Bearish Swing Setup 5.82%
    Expansion Breakdown Bearish Swing Setup 5.82%
    Reversal New Lows Setup Bearish Swing Setup 5.82%
    New 52 Week Low Weakness 5.82%
    Outside Day Range Expansion 5.82%
    Wide Bands Range Expansion 5.82%
    Oversold Stochastic Weakness 5.82%
    1,2,3 Retracement Bearish Bearish Swing Setup -14.16%
    Older End-of-Day Signals for GNLX ...

       Recent Intraday Alerts

    Alert Time
    1.5x Volume Pace 1 minute ago
    Up 5% 34 minutes ago
    Up 3% about 1 hour ago
    Up 2% about 1 hour ago
    Up 1% about 1 hour ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    GNLX Chart by TradingView
    Basic chart:

    Profile

    Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Virotherapy Immunotherapies Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Oncolytic Virus Experimental Cancer Treatments Transgene Sa Treatment Of Ovarian Cancer Treatment Of Pancreatic Cancer

    Is GNLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 5 After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
    Apr 4 All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy
    Apr 1 Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    Feb 2 Genelux files for a $300M mixed securities shelf
    Dec 15 Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)
    Nov 27 HC Wainwright starts Genelux at buy, cites Olvi-Vec potential
    Nov 27 Genelux gets fast track status for Olvi-Vec in ovarian cancer
    Nov 27 Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
    Nov 17 Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%
    Nov 15 Genelux GAAP EPS of -$0.20 misses by $0.02
    See more GNLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 40.98
    52 Week Low 3.33
    Average Volume 137,251
    200-Day Moving Average 15.59
    50-Day Moving Average 6.12
    20-Day Moving Average 4.69
    10-Day Moving Average 3.96
    Average True Range 0.53
    RSI (14) 27.54
    ADX 40.02
    +DI 10.28
    -DI 29.13
    Chandelier Exit (Long, 3 ATRs) 4.90
    Chandelier Exit (Short, 3 ATRs) 4.93
    Upper Bollinger Bands 6.48
    Lower Bollinger Band 2.91
    Percent B (%b) 0.12
    BandWidth 76.06
    MACD Line -0.80
    MACD Signal Line -0.79
    MACD Histogram -0.0055
    Fundamentals Value
    Market Cap 89.5 Million
    Num Shares 26.7 Million
    EPS -1.06
    Price-to-Earnings (P/E) Ratio -3.16
    Price-to-Sales 1003.60
    Price-to-Book 10.42
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.69
    Resistance 3 (R3) 4.83 4.52 4.46
    Resistance 2 (R2) 4.52 4.18 4.45 4.39
    Resistance 1 (R1) 3.94 3.97 3.79 3.80 4.31
    Pivot Point 3.63 3.63 3.56 3.56 3.63
    Support 1 (S1) 3.05 3.29 2.90 2.91 2.39
    Support 2 (S2) 2.74 3.08 2.67 2.31
    Support 3 (S3) 2.16 2.74 2.24
    Support 4 (S4) 2.02